Science Signaling Podcast: 22 May 2012

See allHide authors and affiliations

Sci. Signal.  22 May 2012:
Vol. 5, Issue 225, pp. pc11
DOI: 10.1126/scisignal.2003176

You are currently viewing the abstract.

View Full Text


This Podcast features an interview with Mari Shinohara, senior author of a Research Article published in the 22 May 2012 issue of Science Signaling. Interferon-β (IFN-β) treatment can slow the progression of multiple sclerosis (MS) by reducing inflammation in the nervous system, but it is not effective in all patients. Mari Shinohara’s group studies the effects of IFN-β therapy in a mouse model of MS to understand how this protein can inhibit the inflammation that leads to neurological dysfuntion in human patients. They found that IFN-β therapy is only effective in treating symptoms in the mouse model when development of the disease depends upon the NLRP3 inflammasome, suggesting the possibility that this might also be the reason for the failure of IFN-β therapy in some human MS patients.

View Full Text